NLS XNK Therapeutics

XNK Therapeutics has announced plans to further expand the scope of its technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 […]

XNK Therapeutics has announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s  autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa. “Having the first patient included in this clinical study is a key step in XNK’s development,” […]

XNK Therapeutics is entering into a Phase II clinical study to treat patients with multiple myeloma using its leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa. XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated by Karolinska Institutet. XNK will provide its novel autologous NK cell-based product to the study […]

XNK Therapeutics has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its investigational drug candidate in the treatment of multiple myeloma (MM). Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of the drug candidate, states the company. […]